Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025
Rhea-AI Summary
Revolution Medicines (Nasdaq: RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, will release its Q2 2025 financial results on August 6, 2025, after market close.
The company's senior management will host a webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss quarterly results and provide corporate updates. The webcast will be accessible through the company's investor relations website, with a replay available for at least 14 days following the live presentation.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RVMD gained 0.69%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter of 2025 on Wednesday, August 6, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
FAQ
When will Revolution Medicines (RVMD) report Q2 2025 earnings?
What time is Revolution Medicines' (RVMD) Q2 2025 earnings call?
How can I access Revolution Medicines' (RVMD) Q2 2025 earnings webcast?
What type of cancer treatments is Revolution Medicines (RVMD) developing?
